Transcriptomics

Dataset Information

0

Engineered Antibody Cytokine Chimera Synergizes with DNA-Launched Nanoparticle Vaccines to Potentiate Suppression of Melanoma Proliferation in vivo


ABSTRACT: Cancer immunotherapy has demonstrated great promise with the checkpoint inhibitors being approved as the first-line therapy for some types of cancer, and engineered cytokines like Neo2/15 being evaluated in many studies. In this work, we designed Antibody Cytokine Chimera (ACC) scaffolding cytokine mimetics with full-length tumor-specific antibody. We characterized the pharmacokinetic (PK) and pharmacodynamic (PD) properties of first-generation ACC TA99-Neo2/15, which synergized with DLnano-vaccines in suppressing in vivo melanoma proliferation but caused significant systemic cytokine activation. A novel second-generation ACC TA99-HL2-KOA1, with retained IL-2Rβ/γ binding and attenuated but preserved IL-2Rα, caused significantly lower systemic cytokine activation and non-inferior protection in murine tumor studies. Transcriptomic experiment demonstrated up-regulation of Type I interferon responsive genes, particularly ISG15, in dendritic cells, macrophages and monocytes following TA99-HL2-KOA1 treatment. Characterization of additional ACCs in combination with cancer vaccines will likely be an important area of research for treating melanoma and other types of cancer.

ORGANISM(S): Mus musculus

PROVIDER: GSE159553 | GEO | 2023/03/15

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2012-11-01 | E-GEOD-40350 | biostudies-arrayexpress
2012-11-01 | GSE40350 | GEO
2015-06-16 | E-GEOD-64713 | biostudies-arrayexpress
2015-06-16 | GSE64713 | GEO
2024-08-22 | GSE250205 | GEO
2012-12-31 | E-GEOD-34816 | biostudies-arrayexpress
2021-06-21 | GSE158893 | GEO
2021-06-21 | GSE158915 | GEO
2018-06-01 | GSE76094 | GEO
2019-07-01 | GSE124531 | GEO